What is Neomycin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Neomycin: An Aminoglycoside Antibiotic with Specific Clinical Applications

Neomycin is an aminoglycoside antibiotic primarily used for suppression of intestinal bacteria before surgery, treatment of hepatic encephalopathy, and as a topical antibiotic, though it has significant limitations due to toxicity concerns. 1

Pharmacology and Mechanism of Action

Neomycin is an antibiotic derived from the actinomycete Streptomyces fradiae. It works by inhibiting protein synthesis in susceptible bacterial cells, making it bactericidal in nature. 2

Key pharmacological properties include:

  • Poor absorption from the normal gastrointestinal tract (approximately 97% eliminated unchanged in feces)
  • Rapid suppression of most intestinal bacteria following oral administration, with effects persisting for 48-72 hours
  • Primary activity against gram-negative bacilli with some activity against gram-positive organisms
  • Specific activity against Escherichia coli and Klebsiella-Enterobacter groups
  • No activity against anaerobic bowel flora 2

Clinical Applications

1. Hepatic Encephalopathy

  • Used as an alternative choice for treatment of overt hepatic encephalopathy (Grade II-1, B, 2) 3
  • Works by reducing ammonia-forming bacteria in the intestinal tract 1
  • Often used when other treatments have failed or are contraindicated

2. Preoperative Bowel Preparation

  • Used as adjunctive therapy for preoperative suppression of intestinal bacteria 1
  • Helps reduce bacterial load before gastrointestinal surgery

3. Irritable Bowel Syndrome (IBS)

  • May be used in combination therapy for specific IBS cases
  • Combination of rifaximin and neomycin (85% clinical response) is more effective than neomycin alone (63%) or rifaximin alone (56%) in treating methane-positive IBS patients 4
  • Used in late-onset diarrhea after irinotecan therapy (500 mg bid po) 3

4. Decolonization of Multidrug-Resistant Bacteria

  • Has been studied in combination with colistin for temporary suppression of multidrug-resistant Enterobacteriaceae carriage 3

Toxicity and Safety Concerns

Neomycin has significant toxicity concerns that limit its use:

  1. Ototoxicity: Can cause permanent hearing loss, particularly with prolonged use or systemic absorption 5

  2. Nephrotoxicity: Can cause renal damage, which is usually reversible if detected early 5

  3. Hypersensitivity: Approximately 5-15% of patients with chronic external otitis may develop hypersensitivity to neomycin 1

    • Anaphylactic reactions to neomycin are contraindications for vaccines containing trace amounts of neomycin (e.g., MMR, measles, mumps vaccines) 3
    • Contact dermatitis (delayed-type immune response) is not a contraindication for vaccines containing trace neomycin 3
  4. Systemic Absorption: Even with oral administration, some systemic absorption can occur, posing serious risks including neurotoxicity 1

Dosing and Administration

For oral administration:

  • Available as 500 mg tablets (equivalent to 350 mg neomycin base) 2
  • Typical dosing varies by indication:
    • For hepatic encephalopathy: Used as an alternative choice (specific dosing should follow clinical guidelines) 3
    • For late-onset diarrhea after irinotecan therapy: 500 mg twice daily 3

Special Populations and Precautions

  • Elderly patients: Higher risk of toxicity, requiring careful monitoring of renal function and hearing 1
  • Renal impairment: Requires dose adjustment and careful monitoring 1
  • Pregnancy: Should be used with caution due to potential risks 1

Drug Interactions

Neomycin may interact with other antibiotics:

  • Synergistic effects observed when combined with peptide antibiotics (polymyxin, gramicidin, and bacitracin)
  • No synergy observed when combined with beta-lactams (ampicillin, procaine penicillin) 6

Resistance Concerns

Like other aminoglycosides, bacterial resistance to neomycin is a growing concern, leading to research into modified versions of the drug to overcome resistance mechanisms 7. Careful and appropriate use is essential to minimize the development of resistance.

Alternatives

For most indications, neomycin is not a first-line treatment. Alternative treatments with better safety profiles are often preferred, particularly for long-term use.

For example, in treating hepatic encephalopathy:

  • Lactulose is the first choice for treatment of episodic overt hepatic encephalopathy 3
  • Rifaximin is an effective add-on therapy to lactulose for prevention of hepatic encephalopathy recurrence 3

References

Guideline

Scabies and Intestinal Bacteria Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Neomycin toxicity revisited.

Archives of surgery (Chicago, Ill. : 1960), 1976

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.